Low vitamin B12 diet increases liver homocysteine levels and leads to liver steatosis in rats
Article Sidebar
Main Article Content
Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most widespread chronic liver diseases, caused by the development of insulin resistance. One of the mechanisms involved is a disturbance in insulin signaling by certain toxic substances that interact with one of the proteins responsible for the insulin signaling pathway. Increased homocysteine level, upon disruption of the methionine pathway, is associated with insulin resistance. The aim of this study was to evaluate the effect of hyperhomocysteinemia and insulin resistance (HOMA-IR level) induced by dietary vitamin B12 restriction on liver steatosis.
Methods
A study of laboratory experimental design was conducted involving 18 male Sprague Dawley rats (age 36-40 weeks, BW 300-350 g), that were randomly divided into 3 groups: control, 8-week treatment, and 16-week treatment. Standard AIN-93 diet was administered to the control group, whereas rats in the treatment groups were fed vitamin B12 deficiency-AIN-93M. At the end of treatment, liver homocysteine levels were determined by ELISA, HOMA-IR values were calculated, and steatosis degree of the liver was determined histologically. Statistical analysis was performed using independent t-test.
Results
A significant increase in liver homocysteine levels was found between the control and both the 8- and 16-week treatment groups (p<0.001). HOMA-IR levels were significantly higher in both treatment groups compared to controls (p<0.001). The area of liver steatosis in both treatment groups was significantly larger than that of the control group (p<0.001).
Conclusion
Increased homocysteine levels due to dietary vitamin B12 deficiency induces liver steatosis due to insulin resistance in rats.
Article Details
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
References
Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease: an evolving view. Clin Liver Dis 2018;22:11–21. doi: 10.1016/j.cld.2017.08.003
Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol 2015;7:846–58. doi: 10.4254/wjh.v7.i6.846.
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038–48. doi: 10.1016/j.metabol.2015.12.012.
Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014;20:15539–48. doi: 10.3748/wjg.v20.i42.15539.
Barchetta I, Cimini FA, Cavallo MG. Vitamin D supplementation and non-alcoholic fatty liver disease: present and future. Nutrients 2017;9:pii:E1015. doi: 10.3390/nu9091015.
Bito T, Misaki T, Yabuta Y, Ishikawa T, Kawano T, Watanabe F. Vitamin B12 deficiency results in severe oxidative stress, leading to memory retention impairment in Caenorhabditis elegans. Redox Biol 2017;11:21–9. doi: 10.1016/j.redox.2016.10.013.
Koplay M, Gulcan E, Ozkan F. Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease. J Investig Med 2011;59:1137–40. doi: 10.2310/JIM.0b013e31822a29f5.
Huwait EA, Kumosani TA, Moselhy SS, Mosaoa RM, Yaghmoor SS. Relationship between soil cobalt and vitamin B12 levels in the liver of livestock in Saudi Arabia: role of competing elements in soils. Afr Health Sci 2015;15:993–1008. doi: 10.4314/ahs.v15i3.38.
Mahamid M, Mahroum N, Bragazzi NL, et al. Folate and B12 levels correlate with histological severity in NASH patients. Nutrients 2018;10:440. doi: 10.3390/nu10040440.
Li Z, Gueant-Rodriguez R, Quilliot D, et al. Folate and vitamin B12 status is associated with insulin resistance and metabolic syndrome in morbid obesity. Clin Nutr 2018;37:1700-6. doi: 10.1016/j.clnu.2017.07.008.
Yang N, Yao Z, Miao L, et al. Novel clinical evidence of an association between homocysteine and insulin resistance in patients with hypothyroidism or subclinical hypothyroidism. PLoS One 2015;10:e0125922. doi: 10.1371/journal.pone.0125922.
Charan J, Kantharia ND. How to calculate sample size in animal studies ? J Pharmacol Pharmacother 2013;4:303–6. doi: 10.4103/0976-500X.1197262013.
Andraini T, Yolanda S. Prevention of insulin resistance with Hibiscus sabdariffa Linn. extract in high-fructose fed rat. Med J Indones 2015;23:192-6. http://dx.doi.org/10.13181/mji.v23i4.848.
Antuna-Puente B, Disse E, Rabasa-Lhoret R, Laville M, Capeau J, Bastard JP. How can we measure insulin sensitivity/resistance ? Diabetes Metab 2011;37:179–88. doi: 10.1016/j.diabet.2011.01.002.
Liang W, Menke AL, Driessen A, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One 2014;9:e115922. doi: 10.1371/journal.pone.0115922.
Rastogi A, Shasthry SM, Agarwal A, et al. Non-alcoholic fatty liver disease – histological scoring systems: a large cohort single-center, evaluation study. APMIS 2017;125:962-73. doi: 10.1111/apm.12742.2017;962–73.
Sianipar IR, Ujianti I, Yolanda S, et al. Developing vitamin B12 deficient rat model based on duration of restriction diet: assessment of plasma vitamin B12, homocysteine (Hcy), and blood glucose levels. In: Wulan PPDK, Gozan M, Astutiningsih S, Ramahdita G, Dhelika R, Kreshanti P, editors. 3rd Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, and Medical Devices. Proceedings of the International Symposium of Biomedical Engineering, ISBE; 2018 Aug 6-8; American Institute of Physics Inc.;2019.p.10001.
Mahmood L. The metabolic processes of folic acid and vitamin B12 deficiency. J Health Res Rev 2014;1:5-9. doi: 10.4103/2394-2010.143318.
Mahalle N, Kulkarni MV, Garg MK, Naik SS. Vitamin B12 deficiency and hyperhomocysteinemia as correlates of cardiovascular risk factors in Indian subjects with coronary artery disease. J Cardiol 2013;61:289-94. doi: 10.1016/j.jjcc.2012.11.009.
Feng X, Xu Y. Hyperhomocysteinemia as a metabolic risk factor for glucose intolerance among high-risk groups of Chinese adults. Med Sci Monit 2017;2775–81. doi: 10.12659/msm.905002.
Platt DE, Hariri E, Salameh P, et al. Type II diabetes mellitus and hyperhomocysteinemia: a complex interaction. Diabetol Metab Syndr 2017;9:19. doi: 10.1186/s13098-017-0218-0.
Najib S, Sánchez-Margalet V. Homocysteine thiolactone inhibits insulin-stimulated DNA and protein synthesis: possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation. J Mol Endocrinol 2005;34:119-26. doi: 10.1677/jme.1.01581.
Ebrahimpour A, Vaghari-tabari M, Qujeq D, Moein S. Direct correlation between serum homocysteine level and insulin resistance index in patients with subclinical hypothyroidism: does subclinical hypothyroidism increase the risk of diabetes and cardio vascular disease together ? Diabetes Metab Syndr 2018;12:863-7. doi: 10.1016/j.dsx.2018.05.002.
Zheng S, Xu H, Zhou H, et al. Associations of lipid profiles with insulin resistance and β cell function in adults with normal glucose tolerance and different categories of impaired glucose regulation. PLoS One 2017;12:e0172221. doi: 10.1371/journal.pone.0172221.2017;1–11.
Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014;59:713-23. doi: 10.1002/hep.26672.
Abdul-Ghani MA, De Fronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010, Article ID 476279, 19 pages. doi: 10.1155/2010/476279.
Cook JR, Langlet F, Kido Y, Accili D. Pathogenesis of selective insulin resistance in isolated hepatocytes. J Biol Chem 2015;290:13972-80. doi: 10.1074/jbc.M115.638197.
Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. J Am Med Assoc 2010;303:235–41. doi: 10.1001/jama.2009.2014.
Perry RJ, Samuel VT, Petersen KF, Shulman GI. Insulin resistance and type 2 diabetes. Nature 2014;510:84–91. doi: 10.1038/nature13478.
Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014;146:726–35. http://dx.doi.org/10.1053/j.gastro.2013.11.049.
Gluchowski NL, Becuwe M, Walther TC, Farese Jr RV. Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol 2017;14:343–55. doi: 10.1038/nrgastro.2017.32.
Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59–69. doi: 10.1016/j.freeradbiomed.2011.10.003.
Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591–638. doi: 10.3390/ijms15058591.